查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495360

全球糖組學治療市場：產業分析、規模、佔有率、成長、趨勢、預測（2024-2032）

Glycomic Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 306 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

本報告對全球糖組學治療市場進行了深入分析，並深入瞭解其複雜的動態和未來軌跡。從市場趨勢到成長催化劑、抑制劑和新興模式，我們提供 2024 年至 2032 年有價值的統計數據和預測。

關鍵見解

  • 糖組學治療市場規模（2024 年）：167,615,670,000 美元
  • 預測市場規模（2032 年）5,517.56 億美元
  • 全球市場成長率（2024-2032 年複合年增長率）：16.1%

糖組學治療市場 - 報告範圍：

糖組治療市場包括製藥、生物技術和醫療保健等行業的各種應用。糖組學療法涉及研究和操縱聚醣（糖）以達到治療目的。這些療法在疫苗、癌症治療和傳染病治療的開發中發揮重要作用。該市場服務於廣泛的最終用戶，包括製藥公司、生物技術公司和研究機構，為疾病治療和預防提供先進的解決方案。市場成長是由技術進步、針對性治療需求增加以及醫療保健研究投資增加等因素所推動的。

市場驅動因素：

全球糖組學治療市場受到幾個關鍵成長動力的支持。糖組學的技術進步將增強對聚醣的理解和操縱，並促進新療法的開發。此外，對標靶和個人化醫療不斷增長的需求正在創造對血糖治療的巨大需求。此外，增加對醫療保健研發的投資將刺激聚醣新治療應用的發現，進一步推動市場成長。

市場限制因素：

儘管成長前景廣闊，但糖組學治療市場面臨著與高研發成本、監管障礙和替代療法競爭相關的課題。由於聚醣結構和功能的複雜性，研發需要大量投資，為進入市場的公司帶來了財務課題。治療藥物開發和批准的嚴格監管要求增加了合規負擔並影響市場擴張。此外，來自基因組學和蛋白□□質組學等其他治療方法的競爭對糖組學治療的廣泛使用提出了課題。

市場機會：

由於技術創新、產業聯盟和市場多元化，糖組學治療市場提供了利潤豐厚的成長機會。個人化醫療、免疫療法和合成生物學等新興趨勢正在促使製造商探索糖組治療的新配方和應用。此外，透過策略合作、聯合研究和併購，市場參與者正在擴大產品組合，增強技術能力，並加強在關鍵地區的市場佔有率。此外，增加對醫療保健研究的投資以及政府對技術創新和工業基礎設施的支持力度加大，正在創造有利於市場擴張和多元化的環境。

本報告涵蓋的主要問題

  • 推動全球糖組學治療市場成長的關鍵因素是什麼？
  • 技術進步和產業趨勢如何影響糖組學治療應用和配方的演變？
  • 糖組治療領域的市場參與者面臨哪些主要課題與機會？
  • 哪些產業和地區為糖療法製造商提供了最高的成長潛力？
  • 領先公司正在採取哪些策略來實現糖組治療的差異化並在競爭格局中贏得市場佔有率？

目錄

第 1 章執行摘要

第二章市場概述

  • 市場範圍/分類
  • 市場定義/範圍/限制

第三章市場背景

  • 市場動態
  • 情境預測
  • 機會圖分析
  • 投資可行性矩陣
  • PESTLE 和 Porter 分析
  • 監理狀況
  • 區域母公司市場前景

第四章全球醣組學治療市場分析

  • 2019-2023 年過去的市場規模金額（百萬美元）分析
  • 2024-2032 年當前及未來市場規模金額（百萬美元）預測
    • 年成長趨勢分析
    • 絕對的$機會分析

第 5 章全球醣組學治療市場分析：依類別

  • 簡介/主要發現
  • 2019-2023 年依類別劃分的市場規模金額（百萬美元）績效分析
  • 2024-2032 年當前和未來市場規模價值（百萬美元）的分析和預測（依類別）
    • 隔離
    • 合成
  • 年成長趨勢分析：依類別，2019-2023 年
  • 絕對美元機會分析：依類別劃分，2024-2032 年

第 6 章全球醣組學治療市場分析：依適應症

  • 簡介/主要發現
  • 2019-2023 年依適應症劃分的市場規模（百萬美元）績效分析
  • 2024-2032 年當前和未來市場規模價值（百萬美元）的分析和預測（依指標）
    • 血栓形成/化學預防
    • 貧血
    • 抗沾黏/抗發炎特性
    • 白內障
    • 戈謝病
    • MPS-1□IV
    • 癌症
    • 阿茲海默症
    • A/B 型流感
    • 其他
  • 年成長趨勢分析：依指標劃分，2019-2023 年
  • 絕對機會分析：依跡象劃分，2024 年至 2032 年

第 7 章全球糖組學治療市場分析：依結構

  • 簡介/主要發現
  • 2019-2023 年依結構劃分的市場規模金額（百萬美元）實際分析
  • 2024-2032 年當前和未來市場規模價值（百萬美元）的分析和預測（依結構）
    • 糖蛋白
    • 標靶唾液酸
    • 扎那米韋
    • 奧司他韋
    • 蛋白多醣
    • 糖基磷脂□肌醇 - 錨定蛋白和肝素聚醣
    • 標靶醣胺聚醣
    • 標靶醣脂
    • 其他 - 阿卡波糖、α-葡萄糖甘□、阿洛□
  • 年成長趨勢分析：依結構劃分，2019-2023 年
  • 絕對美元機會分析：依結構劃分，2024-2032 年

第 8 章全球醣組學治療市場分析：依作用機轉

  • 簡介/主要發現
  • 2019-2023 年依作用機制劃分的市場規模（百萬美元）績效分析
  • 依作用機制分析與預測 2024-2032 年當前及未來市場規模價值（百萬美元）
    • 抑制神經氨酸□
    • 促紅血球生成素和酵素替代療法 - ERT
    • 組織纖溶□原激活劑
    • 抑制葡萄糖神經醯胺合成□
    • 白血球介素 1、2、3
    • β和γ幹擾素
  • 年成長趨勢分析：依作用機制，2019-2023 年
  • 絕對機會分析：依行動方式，2024-2032 年

第 9 章全球糖組學治療市場分析：依地區

  • 簡介/主要發現
  • 2019-2023 年依地區劃分的市場規模金額（百萬美元）績效分析
  • 2024-2032 年依地區劃分的當前和未來市場規模價值（百萬美元）分析和預測
    • 北美
    • 拉丁美洲
    • 歐洲
    • 亞太地區
    • 中東/非洲
  • 市場吸引力分析：依地區劃分

第 10 章北美糖組學治療市場分析：依國家

第 11 章拉丁美洲糖組學治療市場分析：依國家

第 12 章歐洲糖組學治療市場分析：依國家

第 13 章亞太地區糖組學治療市場分析：依國家

第 14 章中東和非洲糖組學治療市場分析：依國家

第十五章主要國家糖組學治療市場分析

  • 美國
  • 加拿大
  • 巴西
  • 墨西哥
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 中國
  • 日本
  • 韓國
  • 新加坡
  • 泰國
  • 印尼
  • 澳大利亞
  • 紐西蘭
  • 海灣合作委員會國家
  • 南非
  • 以色列

第十六章市場結構分析

  • 競爭對手儀表板
  • 競爭基準
  • 主要公司市佔率分析

第十七章競爭分析

  • 衝突詳情
    • Intellihep Ltd
    • Protalix Biotherapeutics
    • BioMarin Pharmaceutical Inc.
    • Sanofi
    • Halozyme Therapeutics Inc
    • Bayer AG
    • Alzheon Inc.
    • GlycoMar
    • GlaxoSmithKline Plc
    • F. Hoffmann-La Roche Ltd

第 18 章使用的假設與縮寫

第 19 章研究方法

簡介目錄
Product Code: PMRREP33227

Persistence Market Research presents an in-depth analysis of the Glycomic Therapeutics Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2032.

Key Insights:

  • Glycomic Therapeutics Market Size (2024): USD 167615.67 Million
  • Projected Market Value (2032): USD 551756 Million
  • Global Market Growth Rate (CAGR 2024 to 2032): 16.1%

Glycomic Therapeutics Market - Report Scope:

The Glycomic Therapeutics Market encompasses various applications across industries such as pharmaceuticals, biotechnology, and healthcare. Glycomic therapeutics involve the study and manipulation of glycans (sugars) for therapeutic purposes. These therapeutics play a crucial role in the development of vaccines, cancer treatments, and therapies for infectious diseases. This market caters to a wide range of end-users, including pharmaceutical companies, biotech firms, and research institutions, offering advanced solutions for disease treatment and prevention. Market growth is driven by factors such as technological advancements, increasing demand for targeted therapies, and rising investment in healthcare research.

Market Growth Drivers:

The global Glycomic Therapeutics Market is bolstered by several key growth drivers. Technological advancements in glycomics enhance the understanding and manipulation of glycans, driving the development of novel therapeutics. Moreover, the increasing demand for targeted and personalized medicine creates significant demand for glycomic therapeutics. Additionally, the growing investment in healthcare research and development stimulates the discovery of new therapeutic applications for glycans, further propelling market growth.

Market Restraints:

Despite its promising growth prospects, the Glycomic Therapeutics Market faces challenges related to high research and development costs, regulatory hurdles, and competition from alternative therapies. The complexity of glycan structures and functions requires substantial investment in research and development, posing financial challenges for market players. Stringent regulatory requirements regarding therapeutic development and approval impose compliance burdens, impacting market expansion. Furthermore, competition from other therapeutic approaches, such as genomics and proteomics, poses challenges to the widespread adoption of glycomic therapeutics.

Market Opportunities:

The Glycomic Therapeutics Market presents lucrative growth opportunities driven by technological innovation, industry collaborations, and market diversification. Emerging trends such as personalized medicine, immunotherapy, and synthetic biology inspire manufacturers to explore new formulations and applications for glycomic therapeutics. Moreover, strategic partnerships, research collaborations, and mergers and acquisitions enable market players to expand their product portfolios, enhance their technical capabilities, and strengthen their market presence in key regions. Furthermore, growing investments in healthcare research, coupled with increasing government support for innovation and industrial infrastructure, create a conducive environment for market expansion and diversification.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Glycomic Therapeutics Market globally?
  • How are technological advancements and industry trends shaping the evolution of glycomic therapeutics applications and formulations?
  • What are the key challenges and opportunities facing market participants in the glycomic therapeutics segment?
  • Which industrial sectors and geographic regions offer the highest growth potential for glycomic therapeutics manufacturers?
  • What strategies are leading companies employing to differentiate their glycomic therapeutics offerings and capture market share in the competitive healthcare landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Glycomic Therapeutics Market, including pharmaceutical companies, biotech firms, and research institutions, focus on innovation, product differentiation, and market expansion to gain a competitive edge. These companies invest in research and development to develop advanced glycan manipulation technologies, improve therapeutic efficacy, and explore new applications for glycomic therapeutics. Moreover, strategic collaborations with research institutions, academic partners, and industry associations enable market players to access new technologies, expand their knowledge base, and accelerate product development efforts. Furthermore, emphasis on regulatory compliance, quality assurance, and customer support enhances brand reputation and fosters long-term relationships with customers and stakeholders.

Key Companies Profiled:

  • GlycoMimetics, Inc.
  • Protalix BioTherapeutics, Inc.
  • Angion Biomedica Corp.
  • Oxford GlycoSciences Ltd.
  • GlycoNet
  • GlycoThera GmbH
  • Z Biotech, LLC
  • Sanguine BioSciences, Inc.
  • GLYcoDiag
  • Genentech, Inc.
  • Novartis AG
  • Eli Lilly and Company

Glycomic Therapeutics Market Research Segmentation:

By Class:

  • Isolated
  • Synthetic

By Structures:

  • Glycoproteins
  • Targeting Sialic Acid
  • Proteoglycans
  • Targeting Glycosaminoglycans
  • Targeting Glycosylphosphatidylinositol (GPI) - Anchored Proteins and Heparin Based Glycans
  • Targeting Glycosphingolipids
  • Others

By Indications:

  • Thrombosis and Chemoprophylaxis
  • Anaemia
  • Anti-adhesive and Anti-inflammatory
  • Cataracts
  • Gaucher's disease
  • MPS-1 and IV
  • Cancer
  • Alzheimer's disease
  • Influenza type A and B
  • Others

By Mode of Action:

  • Inhibits Neuraminidase
  • Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
  • Erythropoietin and Enzyme Replacement Therapy
  • Tissue Plasminogen Activator
  • Inhibits Glucosylceramide Synthase
  • Interleukin 1, 2 & 3
  • Beta and Gamma Interferons
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Technology Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Background

  • 3.1. Market Dynamics
    • 3.1.1. Drivers
    • 3.1.2. Restraints
    • 3.1.3. Opportunity
    • 3.1.4. Trends
  • 3.2. Scenario Forecast
    • 3.2.1. Demand in Optimistic Scenario
    • 3.2.2. Demand in Likely Scenario
    • 3.2.3. Demand in Conservative Scenario
  • 3.3. Opportunity Map Analysis
  • 3.4. Investment Feasibility Matrix
  • 3.5. PESTLE and Porter's Analysis
  • 3.6. Regulatory Landscape
    • 3.6.1. By Key Regions
    • 3.6.2. By Key Countries
  • 3.7. Regional Parent Market Outlook

4. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast, 2024-2032

  • 4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
  • 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2032
    • 4.2.1. Y-o-Y Growth Trend Analysis
    • 4.2.2. Absolute $ Opportunity Analysis

5. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Class

  • 5.1. Introduction / Key Findings
  • 5.2. Historical Market Size Value (US$ Mn) Analysis By Class, 2019-2023
  • 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Class, 2024-2032
    • 5.3.1. Isolated
    • 5.3.2. Synthetic
  • 5.4. Y-o-Y Growth Trend Analysis By Class, 2019-2023
  • 5.5. Absolute $ Opportunity Analysis By Class, 2024-2032

6. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Indication

  • 6.1. Introduction / Key Findings
  • 6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2019-2023
  • 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2024-2032
    • 6.3.1. Thrombosis and Chemoprophylaxis
    • 6.3.2. Anaemia
    • 6.3.3. Anti-adhesive and Anti-inflammatory
    • 6.3.4. Cataract
    • 6.3.5. Gaucher's Diseases
    • 6.3.6. MPS-1 & IV
    • 6.3.7. Cancer
    • 6.3.8. Alzheimer's
    • 6.3.9. Influenza Type A and B
    • 6.3.10. Others
  • 6.4. Y-o-Y Growth Trend Analysis By Indication, 2019-2023
  • 6.5. Absolute $ Opportunity Analysis By Indication, 2024-2032

7. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Structures

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size Value (US$ Mn) Analysis By Structures , 2019-2023
  • 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Structures , 2024-2032
    • 7.3.1. Glycoproteins
    • 7.3.2. Targeting Sialic Acid
    • 7.3.3. Zanamivir
    • 7.3.4. Oseltamivir
    • 7.3.5. Proteoglycans
    • 7.3.6. Glycosylphosphatidylinositol - Anchored Proteins and Heparin Based Glycans
    • 7.3.7. Targeting Glycosaminoglycans
      • 7.3.7.1. Heparin
      • 7.3.7.2. Hyaluronan - HA
      • 7.3.7.3. Laronidase
      • 7.3.7.4. Galsulfase - Naglazyme
      • 7.3.7.5. Hyaluronidase - Cumulase
      • 7.3.7.6. Others
    • 7.3.8. Targeting Glycosphingolipids
      • 7.3.8.1. Imiglucerase - Cerezyme
      • 7.3.8.2. Agalsidase - Fabrazyme
      • 7.3.8.3. N-butyl-deoxynojirimycin - DNJ
      • 7.3.8.4. Others
    • 7.3.9. Others - Acarbose, Alglucosidase Alfa, Allosamidin
  • 7.4. Y-o-Y Growth Trend Analysis By Structures , 2019-2023
  • 7.5. Absolute $ Opportunity Analysis By Structures , 2024-2032

8. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Mode of Action

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size Value (US$ Mn) Analysis By Mode of Action, 2019-2023
  • 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Mode of Action, 2024-2032
    • 8.3.1. Inhibits Neuraminidase
    • 8.3.2. Erythhropoietin and Enzyme Replacement Therapy - ERT
    • 8.3.3. Tissue Plasminogen Activator
    • 8.3.4. Inhibits Glucosylceramide Synthase
    • 8.3.5. Interleukin 1 and 2 and 3
    • 8.3.6. Beta and Gamma Interferons
    • 8.3.7. Others
  • 8.4. Y-o-Y Growth Trend Analysis By Mode of Action, 2019-2023
  • 8.5. Absolute $ Opportunity Analysis By Mode of Action, 2024-2032

9. Global Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. MEA
  • 9.4. Market Attractiveness Analysis By Region

10. North America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 10.2.1. By Country
      • 10.2.1.1. U.S.
      • 10.2.1.2. Canada
    • 10.2.2. By Class
    • 10.2.3. By Indication
    • 10.2.4. By Structures
    • 10.2.5. By Mode of Action
  • 10.3. Market Attractiveness Analysis
    • 10.3.1. By Country
    • 10.3.2. By Class
    • 10.3.3. By Indication
    • 10.3.4. By Structures
    • 10.3.5. By Mode of Action
  • 10.4. Key Takeaways

11. Latin America Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 11.2.1. By Country
      • 11.2.1.1. Brazil
      • 11.2.1.2. Mexico
      • 11.2.1.3. Rest of Latin America
    • 11.2.2. By Class
    • 11.2.3. By Indication
    • 11.2.4. By Structures
    • 11.2.5. By Mode of Action
  • 11.3. Market Attractiveness Analysis
    • 11.3.1. By Country
    • 11.3.2. By Class
    • 11.3.3. By Indication
    • 11.3.4. By Structures
    • 11.3.5. By Mode of Action
  • 11.4. Key Takeaways

12. Europe Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 12.2.1. By Country
      • 12.2.1.1. Germany
      • 12.2.1.2. U.K.
      • 12.2.1.3. France
      • 12.2.1.4. Spain
      • 12.2.1.5. Italy
      • 12.2.1.6. Rest of Europe
    • 12.2.2. By Class
    • 12.2.3. By Indication
    • 12.2.4. By Structures
    • 12.2.5. By Mode of Action
  • 12.3. Market Attractiveness Analysis
    • 12.3.1. By Country
    • 12.3.2. By Class
    • 12.3.3. By Indication
    • 12.3.4. By Structures
    • 12.3.5. By Mode of Action
  • 12.4. Key Takeaways

13. Asia Pacific Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 13.2.1. By Country
      • 13.2.1.1. China
      • 13.2.1.2. Japan
      • 13.2.1.3. South Korea
      • 13.2.1.4. Singapore
      • 13.2.1.5. Thailand
      • 13.2.1.6. Indonesia
      • 13.2.1.7. Australia
      • 13.2.1.8. New Zealand
      • 13.2.1.9. Rest of Asia Pacific
    • 13.2.2. By Class
    • 13.2.3. By Indication
    • 13.2.4. By Structures
    • 13.2.5. By Mode of Action
  • 13.3. Market Attractiveness Analysis
    • 13.3.1. By Country
    • 13.3.2. By Class
    • 13.3.3. By Indication
    • 13.3.4. By Structures
    • 13.3.5. By Mode of Action
  • 13.4. Key Takeaways

14. MEA Glycomic Therapeutics Market Analysis 2019-2023 and Forecast 2024-2032, By Country

  • 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2032
    • 14.2.1. By Country
      • 14.2.1.1. GCC Countries
      • 14.2.1.2. South Africa
      • 14.2.1.3. Israel
      • 14.2.1.4. Rest of MEA
    • 14.2.2. By Class
    • 14.2.3. By Indication
    • 14.2.4. By Structures
    • 14.2.5. By Mode of Action
  • 14.3. Market Attractiveness Analysis
    • 14.3.1. By Country
    • 14.3.2. By Class
    • 14.3.3. By Indication
    • 14.3.4. By Structures
    • 14.3.5. By Mode of Action
  • 14.4. Key Takeaways

15. Key Countries Glycomic Therapeutics Market Analysis

  • 15.1. U.S.
    • 15.1.1. Pricing Analysis
    • 15.1.2. Market Share Analysis, 2024
      • 15.1.2.1. By Class
      • 15.1.2.2. By Indication
      • 15.1.2.3. By Structures
      • 15.1.2.4. By Mode of Action
  • 15.2. Canada
    • 15.2.1. Pricing Analysis
    • 15.2.2. Market Share Analysis, 2024
      • 15.2.2.1. By Class
      • 15.2.2.2. By Indication
      • 15.2.2.3. By Structures
      • 15.2.2.4. By Mode of Action
  • 15.3. Brazil
    • 15.3.1. Pricing Analysis
    • 15.3.2. Market Share Analysis, 2024
      • 15.3.2.1. By Class
      • 15.3.2.2. By Indication
      • 15.3.2.3. By Structures
      • 15.3.2.4. By Mode of Action
  • 15.4. Mexico
    • 15.4.1. Pricing Analysis
    • 15.4.2. Market Share Analysis, 2024
      • 15.4.2.1. By Class
      • 15.4.2.2. By Indication
      • 15.4.2.3. By Structures
      • 15.4.2.4. By Mode of Action
  • 15.5. Germany
    • 15.5.1. Pricing Analysis
    • 15.5.2. Market Share Analysis, 2024
      • 15.5.2.1. By Class
      • 15.5.2.2. By Indication
      • 15.5.2.3. By Structures
      • 15.5.2.4. By Mode of Action
  • 15.6. U.K.
    • 15.6.1. Pricing Analysis
    • 15.6.2. Market Share Analysis, 2024
      • 15.6.2.1. By Class
      • 15.6.2.2. By Indication
      • 15.6.2.3. By Structures
      • 15.6.2.4. By Mode of Action
  • 15.7. France
    • 15.7.1. Pricing Analysis
    • 15.7.2. Market Share Analysis, 2024
      • 15.7.2.1. By Class
      • 15.7.2.2. By Indication
      • 15.7.2.3. By Structures
      • 15.7.2.4. By Mode of Action
  • 15.8. Spain
    • 15.8.1. Pricing Analysis
    • 15.8.2. Market Share Analysis, 2024
      • 15.8.2.1. By Class
      • 15.8.2.2. By Indication
      • 15.8.2.3. By Structures
      • 15.8.2.4. By Mode of Action
  • 15.9. Italy
    • 15.9.1. Pricing Analysis
    • 15.9.2. Market Share Analysis, 2024
      • 15.9.2.1. By Class
      • 15.9.2.2. By Indication
      • 15.9.2.3. By Structures
      • 15.9.2.4. By Mode of Action
  • 15.10. China
    • 15.10.1. Pricing Analysis
    • 15.10.2. Market Share Analysis, 2024
      • 15.10.2.1. By Class
      • 15.10.2.2. By Indication
      • 15.10.2.3. By Structures
      • 15.10.2.4. By Mode of Action
  • 15.11. Japan
    • 15.11.1. Pricing Analysis
    • 15.11.2. Market Share Analysis, 2024
      • 15.11.2.1. By Class
      • 15.11.2.2. By Indication
      • 15.11.2.3. By Structures
      • 15.11.2.4. By Mode of Action
  • 15.12. South Korea
    • 15.12.1. Pricing Analysis
    • 15.12.2. Market Share Analysis, 2024
      • 15.12.2.1. By Class
      • 15.12.2.2. By Indication
      • 15.12.2.3. By Structures
      • 15.12.2.4. By Mode of Action
  • 15.13. Singapore
    • 15.13.1. Pricing Analysis
    • 15.13.2. Market Share Analysis, 2024
      • 15.13.2.1. By Class
      • 15.13.2.2. By Indication
      • 15.13.2.3. By Structures
      • 15.13.2.4. By Mode of Action
  • 15.14. Thailand
    • 15.14.1. Pricing Analysis
    • 15.14.2. Market Share Analysis, 2024
      • 15.14.2.1. By Class
      • 15.14.2.2. By Indication
      • 15.14.2.3. By Structures
      • 15.14.2.4. By Mode of Action
  • 15.15. Indonesia
    • 15.15.1. Pricing Analysis
    • 15.15.2. Market Share Analysis, 2024
      • 15.15.2.1. By Class
      • 15.15.2.2. By Indication
      • 15.15.2.3. By Structures
      • 15.15.2.4. By Mode of Action
  • 15.16. Australia
    • 15.16.1. Pricing Analysis
    • 15.16.2. Market Share Analysis, 2024
      • 15.16.2.1. By Class
      • 15.16.2.2. By Indication
      • 15.16.2.3. By Structures
      • 15.16.2.4. By Mode of Action
  • 15.17. New Zealand
    • 15.17.1. Pricing Analysis
    • 15.17.2. Market Share Analysis, 2024
      • 15.17.2.1. By Class
      • 15.17.2.2. By Indication
      • 15.17.2.3. By Structures
      • 15.17.2.4. By Mode of Action
  • 15.18. GCC Countries
    • 15.18.1. Pricing Analysis
    • 15.18.2. Market Share Analysis, 2024
      • 15.18.2.1. By Class
      • 15.18.2.2. By Indication
      • 15.18.2.3. By Structures
      • 15.18.2.4. By Mode of Action
  • 15.19. South Africa
    • 15.19.1. Pricing Analysis
    • 15.19.2. Market Share Analysis, 2024
      • 15.19.2.1. By Class
      • 15.19.2.2. By Indication
      • 15.19.2.3. By Structures
      • 15.19.2.4. By Mode of Action
  • 15.20. Israel
    • 15.20.1. Pricing Analysis
    • 15.20.2. Market Share Analysis, 2024
      • 15.20.2.1. By Class
      • 15.20.2.2. By Indication
      • 15.20.2.3. By Structures
      • 15.20.2.4. By Mode of Action

16. Market Structure Analysis

  • 16.1. Competition Dashboard
  • 16.2. Competition Benchmarking
  • 16.3. Market Share Analysis of Top Players
    • 16.3.1. By Regional
    • 16.3.2. By Class
    • 16.3.3. By Indication
    • 16.3.4. By Structures
    • 16.3.5. By Mode of Action

17. Competition Analysis

  • 17.1. Competition Deep Dive
    • 17.1.1. Intellihep Ltd
      • 17.1.1.1. Overview
      • 17.1.1.2. Product Portfolio
      • 17.1.1.3. Profitability by Market Segments
      • 17.1.1.4. Sales Footprint
      • 17.1.1.5. Strategy Overview
        • 17.1.1.5.1. Marketing Strategy
    • 17.1.2. Protalix Biotherapeutics
      • 17.1.2.1. Overview
      • 17.1.2.2. Product Portfolio
      • 17.1.2.3. Profitability by Market Segments
      • 17.1.2.4. Sales Footprint
      • 17.1.2.5. Strategy Overview
        • 17.1.2.5.1. Marketing Strategy
    • 17.1.3. BioMarin Pharmaceutical Inc.
      • 17.1.3.1. Overview
      • 17.1.3.2. Product Portfolio
      • 17.1.3.3. Profitability by Market Segments
      • 17.1.3.4. Sales Footprint
      • 17.1.3.5. Strategy Overview
        • 17.1.3.5.1. Marketing Strategy
    • 17.1.4. Sanofi
      • 17.1.4.1. Overview
      • 17.1.4.2. Product Portfolio
      • 17.1.4.3. Profitability by Market Segments
      • 17.1.4.4. Sales Footprint
      • 17.1.4.5. Strategy Overview
        • 17.1.4.5.1. Marketing Strategy
    • 17.1.5. Halozyme Therapeutics Inc
      • 17.1.5.1. Overview
      • 17.1.5.2. Product Portfolio
      • 17.1.5.3. Profitability by Market Segments
      • 17.1.5.4. Sales Footprint
      • 17.1.5.5. Strategy Overview
        • 17.1.5.5.1. Marketing Strategy
    • 17.1.6. Bayer AG
      • 17.1.6.1. Overview
      • 17.1.6.2. Product Portfolio
      • 17.1.6.3. Profitability by Market Segments
      • 17.1.6.4. Sales Footprint
      • 17.1.6.5. Strategy Overview
        • 17.1.6.5.1. Marketing Strategy
    • 17.1.7. Alzheon Inc.
      • 17.1.7.1. Overview
      • 17.1.7.2. Product Portfolio
      • 17.1.7.3. Profitability by Market Segments
      • 17.1.7.4. Sales Footprint
      • 17.1.7.5. Strategy Overview
        • 17.1.7.5.1. Marketing Strategy
    • 17.1.8. GlycoMar
      • 17.1.8.1. Overview
      • 17.1.8.2. Product Portfolio
      • 17.1.8.3. Profitability by Market Segments
      • 17.1.8.4. Sales Footprint
      • 17.1.8.5. Strategy Overview
        • 17.1.8.5.1. Marketing Strategy
    • 17.1.9. GlaxoSmithKline Plc
      • 17.1.9.1. Overview
      • 17.1.9.2. Product Portfolio
      • 17.1.9.3. Profitability by Market Segments
      • 17.1.9.4. Sales Footprint
      • 17.1.9.5. Strategy Overview
        • 17.1.9.5.1. Marketing Strategy
    • 17.1.10. F. Hoffmann-La Roche Ltd
      • 17.1.10.1. Overview
      • 17.1.10.2. Product Portfolio
      • 17.1.10.3. Profitability by Market Segments
      • 17.1.10.4. Sales Footprint
      • 17.1.10.5. Strategy Overview
        • 17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology